Compare MBNKO & GRMLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Medallion Bank Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series G par value $1.00 per share
Current Price
| Metric | MBNKO | GRMLW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 142 | 5 |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
| Metric | MBNKO | GRMLW |
|---|---|---|
| Price | $25.21 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 28.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.61 | $0.10 |
| 52 Week High | $28.00 | $0.38 |
| Indicator | MBNKO | GRMLW |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 47.70 |
| Support Level | $24.78 | $0.22 |
| Resistance Level | $25.43 | $0.29 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 30.59 | 24.59 |
Medallion Bank is engaged in providing consumer loans, raising deposits, and managing other banking activities. It offers affordable financing for home improvement contractors, including window, siding, and roof replacements; kitchen, bath, and basement remodels; HVAC (Heating Ventilation and Air Conditioning), and solar PV installations. Medallion also offers recreation financing for new and used motorhomes, towable RVs, truck campers, cargo trailers, utility trailers, horse trailers, and a variety of ATVs and other power sport vehicles. Its segments are Recreation, Home Improvement, and Other. The bank generates maximum revenue from the Recreation segment.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.